Blog
RSS FeedPosted by Michael Wonder on 10 Nov 2020
ICER provides second update to pricing models for remdesivir as a treatment for COVID-19
10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...
Posted by Michael Wonder on 10 Oct 2020
In landmark international program, HTA agencies around the world access ICER's customisable COVID-19 cost-effectiveness model
9 October 2020 - Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 30 Mar 2018
ICER announces new program to make available draft executable economic models during drug assessment review process
30 March 2018 - Pilot program will allow more extensive evaluation of draft economic models used in ICER's reports. ...